Kirkland & Ellis is advising Summit Partners on the sale of Viroclinics-DDL to Cerba Healthcare, a portfolio company of EQT Partners. Viroclinics is a virology contract research organization, serving the biopharmaceutical community with a broad range of preclinical, clinical diagnostic, assay development and clinical trial logistics services. The transaction is subject to regulatory approvals and customary conditions, such as completion of the consultation procedure with Central Works Council of Viroclinics-DDL. The acquisition is expected to close by end of Q1 2022.
The Kirkland team was led by corporate partners Roger Johnson and Adrian Duncan and associates George Rawlinson, Melissa Sawyer and Katy Henman, debt finance partners Chris Shield and Leon Daoud and associate Marina Fatsis, antitrust partner Sally Evans and associate Alexandre Rouhette and tax partner Ian Ferreira and associate Rohit Pisal.